DSDenise Rossato Silva

Denise Rossato Silva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Denise Rossato Silva has a total of 518 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Vitamin D deficiency in patients with tuberculosis: prevalence, risk factors and treatment outcomes

    by Maiana Silva Da Silva, André Kulzer Santos, Raimunda Sinthia Lima de Braga, Allanamara Pereira Marinho, Renata Nunes de Almeida, Carolina Neves Garcia, Giovana Rodrigues Pereira, Denise Rossato Silva

    Although vitamin D deficiency is common in tuberculosis (TB) patients, several studies demonstrated that it may not influence treatment response. The aim of this study was to evaluate the prevalence and risk factors of vitamin D deficiency in a group of TB patients and to assess whether vitamin D deficiency influences TB treatment outcomes. All patients ≥18 years of age undergoing TB treatment at the Alvorada Pulmonology Department were invited to participate in the study. Blood samples were collected to check the level of vitamin D. TB treatment outcomes were collected. In total, 106 patients met the inclusion criteria and were included in the study. The mean vitamin D level was 35.1±16.4 ng/mL. The vitamin D status was classified as normal in 63 (59.4%) patients, insufficiency in 26 (24.5%), deficiency in 12 (11.3%), and severe deficiency in 5 (4.7%). The prevalence of vitamin D deficiency was 16.0%. HIV and diabetes mellitus were more frequent in groups with insufficient and deficient vitamin D compared with the group with normal vitamin D (p=0.041 and p=0.011, respectively). Cured TB case as the treatment outcome was registered less frequently in the group with deficient vitamin D (p=0.016), with confounding factors being HIV and diabetes mellitus. In conclusion, 16.0% of TB patients had vitamin D deficiency in the present study, and HIV and diabetes mellitus were factors associated with vitamin D insufficiency and deficiency. The wide variation in results between studies probably reflects regional variations, which emphasizes the need to understand the local reality. More robust studies are needed to evaluate the effect of vitamin D deficiency on treatment cure rates.

  • Open Access

    Envisioning the future of the Jornal Brasileiro de Pneumologia

    by Marcia Margaret Menezes Pizzichini, Denise Rossato Silva

  • Open Access

    Treatment completion rates and adverse effects of three months of once-weekly isoniazid plus rifapentine for latent tuberculosis infection

    by Tiene Heidy Maoski1, Giovana Rodrigues Pereira2, André Kulzer Santos3, Raimunda Sinthia Lima de Braga3, Marina Scheffer de Souza3, Gean Souza Ramos3, Allanamara Pereira Marinho3, 4 Renata Ullmann de Brito Neves1, 3 Denise Rossato Silva1

    Objective: Preventive treatment of active tuberculosis is one of the main strategies for reducing the incidence of tuberculosis. We sought to evaluate the rates of latent tuberculosis infection (LTBI) treatment completion with three months of once-weekly isoniazid plus rifapentine (3HP) and compare them with those for six to nine months of daily isoniazid (6H/9H). Methods: This was a retrospective cross-sectional study. Consecutive patients undergoing LTBI treatment with 3HP or 6H/9H were included in the study. Treatment completion rates and adverse effects were analyzed. Results: A total of 226 patients were included in the study: 113 in the 3HP group and 113 in the 6H/9H group. The frequency of adverse effects was not significantly different between the 3HP and 6H/9H groups. The 3HP group had a higher treatment completion rate (93.8%) than did the 6H/9H group (84.1%), the difference being significant. Conclusions: The rates of LTBI treatment completion appear to be higher with 3HP than with 6H/9H. Health care professionals should be vigilant in managing adverse effects to further maximize LTBI treatment completion.


  • Open Access

    Lateral flow urine lipoarabinomannan assay for tuberculosis diagnosis in HIV-positive inpatients and outpatients

    by 2 Giovana Rodrigues Pereira1, Márcia Silva Barbosa2, Carina Secchi2, Maiara Priscila dos Passos2, André Kulzer Santos3, Raimunda Sinthia Lima de Braga3, Marina Scheffer de Souza3, Gean Souza Ramos3, João Vitor Vigne Duz3, 3 Denise Rossato Silva1

    Objective: To evaluate tuberculosis diagnosis with the use of the lateral flow urine lipoarabinomannan assay (LF-LAM) in addition to the Xpert® MTB/RIF Ultra assay on sputum in HIV-positive inpatients and outpatients. Methods: This was a prospective cross-sectional study including HIV-positive patients = 18 years of age with an indication for LF-LAM in accordance with Brazilian National Ministry of Health criteria. Results: A total of 140 patients were included in the study. LF-LAM was positive in 23 (16.4%). An additional 12 (8.6%) were diagnosed with the aid of LF-LAM, this increase in tuberculosis detection being statistically significant. LF-LAM-positive patients were younger and had lower CD4 counts in comparison with LF-LAM-negative patients. Smoking was more common among LF-LAM-negative patients than among LF-LAM-positive patients. Conclusions: The use of LF-LAM significantly increases the detection of tuberculosis in HIV-positive patients, mostly in those who are hospitalized. These findings highlight the utility of LF-LAM, especially in regions with high tuberculosis and HIV infection incidence.


  • Open Access

    Latent tuberculosis infection in patients with psoriasis using biologic therapies

    by Fernanda Luiza Staub, André Kulzer Santos, Raimunda Sinthia Lima de Braga, Marina Scheffer de Souza, João Vitor Vigne Duz, Gean Souza Ramos, Juliana Catucci Boza, Denise Rossato Silva

    Some studies have demonstrated a high prevalence of latent tuberculosis infection (LTBI) in patients with psoriasis and a higher risk of active tuberculosis (TB) in patients with severe psoriasis. The objective of this study is to identify the prevalence of LTBI before starting treatment with different biologicals and to identify the prevalence of LTBI and active TB while using these medications. We conducted a cross-sectional study with retrospective data collection in the outpatient department of dermatology at a general, tertiary care, university-affiliated hospital. The electronic medical records of all adult patients (≥18 years old) with psoriasis undergoing treatment with biologics were reviewed, and information about psoriasis, the type of biological therapy used, and the tuberculin skin test (TST) results were collected. The patients included had an indication for the TST test according to the Ministry of Health. In total, 126 patients were included in the study. The median duration of disease was 20 years. A total of 31 patients (24.6%) had LTBI diagnosed at screening before the use of biologicals, and an additional 17 (17.9%) patients had a diagnosis of LTBI during biological therapy. There were no cases of active TB during treatment with biologicals. There was no difference in the prevalence of LTBI during treatment with tumor necrosis factor inhibitors, interleukin (IL)-17 inhibitors, IL-23 inhibitors, and IL-12/23 inhibitors (p=0.228). In conclusion, we found that 24.6% of patients with psoriasis in an endemic TB region had LTBI. Additionally, 16.8% had a diagnosis of LTBI during biological therapy. Our data corroborate the recommendation that patients who live in high TB incidence settings should be tested annually for LTBI.


  • Open Access

    Bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) for multidrug- or rifampin-resistant tuberculosis: a systematic review

    by Denise Rossato Silva, Flávia Fonseca Fernandes, Juliana Carvalho Ferreira, Wanderley Bernando, Margareth Maria Pretti Dalcolmo, Fernanda Dockhorn Costa Johansen, Fernanda Carvalho de Queiroz Mello

    Objective: To evaluate the available evidence comparing the use of the bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) regimen for 6 months with that of standard-of-care regimens for patients with multidrug-resistant or rifampin-resistant tuberculosis (MDR/RR-TB). Methods: This was a systematic review of clinical trials comparing the use of the BPaLM regimen with the standard of care in patients with MDR/RR-TB. The main outcome measure was an unfavorable endpoint (a composite of death, treatment failure, treatment discontinuation, loss to follow-up, and recurrence), and secondary outcome measures included adverse events and serious adverse events. We searched the MEDLINE, EMBASE, Google Scholar, LILACS, and ClinicalTrials.gov databases, from their inception to January 31, 2024, with no limitation as to language or year of publication. The risk of bias was assessed by using the Cochrane risk-of-bias tool, and the quality of evidence was based on the Grading of Recommendations Assessment, Development and Evaluation approach. Results: A total of 3,668 studies were retrieved; only one (a randomized clinical trial) met the inclusion criteria and was included. In patients with MDR/RR-TB, treatment with the BPaLM regimen, when compared with the standard of care, reduced the risk of an unfavorable outcome (composite, number needed to treat [NNT] = 7); early treatment discontinuation (NNT = 8); adverse events and discontinuation (NNT = 12); and serious adverse events (NNT = 5). Conclusions: This systematic review of the use of BPaLM in patients with MDR/RR-TB, although it included only one study, showed that BPaLM is more effective than is the standard of care and has a better safety profile. That has major implications for guidelines on the treatment of MDR/RR-TB.


  • Open Access

    Vaccination in post-tuberculosis lung disease management: A review of the evidence

    by M.J. Nasiri, D.R. Silva, F. Rommasi, M.M. Zahmatkesh, Z. Tajabadi, F. Khelghati, T. Sarmastzadeh, R. Centis, L. D'AMbrosio, S. Bombarda, et al.

    Post-tuberculosis lung disease (PTLD), as other chronic respiratory disorders, may have infectious complications; some of them can be prevented with vaccinations. So far, no document has discussed the potential role of vaccination in PTLD. Therefore, the objective of this review was to describe vaccination recommendations to prevent infections potentially capable of complicating PTLD. A non-systematic review of the literature was conducted. The following keywords were used: tuberculosis, vaccination, vaccines and PTLD. PubMed/MEDLINE and Embase were used as the search engine, focusing on English-language literature only. We identified 9 vaccines potentially useful in PTLD. Influenza, pneumococcal and anti-COVID-19 vaccinations should be recommended. Patients with PTLD can also benefit from vaccination against shingles. Vaccination against pertussis is mainly relevant during childhood. Diphtheria, tetanus and measles vaccination are recommended for general population and should be considered in patients with PTLD not previously vaccinated. Tdap (Tetanus, diphtheria, and pertussis) booster should be repeated in every adult every ten years. Vaccination against BCG retains its importance during early childhood in countries where TB is endemic. Vaccination deserves to be considered among the strategies to prevent and/or mitigate PTLD complications. Further evidence is necessary to better understand which vaccines have the greatest impact and cost-benefit.


  • Prevalence and associated risk factors of post-COVID-19 syndrome in healthcare workers

    by Ana Cláudia Vasconcellos Azeredo, André Külzer Santos, Raimunda Sinthia Lima de Braga, João Vitor Vigne Duz, Marina Scheffer de Souza, Denise Rossato Silva

    Given the global burden of COVID-19 among healthcare workers (HCWs), it is expected that they face an elevated risk of developing post-COVID-19 syndrome. The objectives of this study were to evaluate the prevalence of post-COVID-19 syndrome and associated risk factors in HCWs followed for a median time of 18 months by conducting a retrospective cohort study. All HCWs with confirmed COVID-19 during the period from January 2021 to December 2022 were included in the study. HCWs were regularly assessed after COVID-19 diagnosis, so post-COVID-19 syndrome data could be collected. During the study period, 463 HCWs were included in the study, 227 (49.0%) of which experienced post-COVID-19 syndrome. The most common persistent symptoms were fatigue (n = 147 [32.5%]), memory disorders (n = 98 [21.5%]), dyspnea (n = 73 [16.0%]), anxiety/depression (n = 69 [15.0%]), and cough (n = 43 [9.4%]). Female sex and obesity were statistically associated with the development of post-COVID-19 syndrome. A high prevalence of post-COVID-19 syndrome in HCWs was found. Female sex and obesity appear to be risk factors associated with a higher prevalence of post-COVID-19 syndrome. Special attention should be given to these patients with risk factors during follow-up in the COVID-19 recovery period.


  • Open Access

    Expert views on screening for tuberculosis infection in patients commencing treatment with a biologic agent

    by 2 Adiba Sultana1, Giovanni Battista Migliori3, 4 Lia D’aMbrosio, José-María García-García5, Denise Rossato Silva6, Luis Adrian Rendon5, Luigi R Codecasa7, Francois-Xavier Blanc8, Simon Tiberi9, 11 Catherine W M Ong10, et al.

    Objective: Many biologic agents cause some degree of immunosuppression, which can increase the risk of reactivation of tuberculosis infection (TBI). This risk is variable between individual biologics. We aimed to assess current (and recommended) clinical practice of TBI screening and treatment among patients initiating treatment with biologic agents. Methods: An online questionnaire was distributed via email to members of the Global Tuberculosis Network and associated professional organisations to seek insights into the screening for and treatment of TBI in patients treated with biologics. Results: A total of 163 respondents in 27 countries answered at least one question. For all biologics described in the questionnaire, respondents advised increasing screening relative to current practice. Observed and supported TBI screening rates in patients treated with TNF-a inhibitors were high, especially for older TNF-a inhibitors. Most participants supported TBI screening in patients treated with B- or T-cell inhibitors but not in those treated with interleukin inhibitors. Guideline awareness was higher for TNF-a inhibitors than for other biologic classes (79% vs. 34%). Conclusions: Although respondents stated that TBI screening rates are lower than what they consider ideal, there was a tendency to recommend TBI screening in patients treated with biologics not known to be associated with an increased risk of TBI. As a result, there is a potential risk of over-screening and over-treatment of TBI, potentially causing harm, in patients treated with biologics other than TNF-a inhibitors. There is a need to research the risk of TBI associated with biologics and for guidelines to address the spectrum of TBI risk across all types of biologics.


  • Clinical characteristics, outcomes and persistent symptoms of pregnant women with COVID ‐19: A retrospective cohort study

    by Ana Paula Orlandi Ghizzoni, André Kulzer Santos, Raimunda Sinthia Lima de Braga, João Vitor Vigne Duz, Vitoria Dall’AGnol Bouvier, Marina Scheffer de Souza, Denise Rossato Silva

    Objective: The aim of this study was to evaluate the clinical characteristics and outcomes of pregnant women with COVID‐19 and to compare with pregnant women without COVID‐19. In addition, in the subgroup of patients who were symptomatic at the time of diagnosis, the persistence of symptoms was assessed. Methods: This was a retrospective cohort study. All pregnant women aged ≥18 years, admitted to the maternity ward from March 2020 to September 2023 were included in the study. All patients admitted were routinely screened for SARS‐CoV‐2. Clinical characteristics and outcomes were registered. Results: During the study period, 880 patients met the inclusion and were included in the analysis: 385 were COVID‐19 positive and 495 were COVID‐19 negative. In a multivariate analysis of the outcomes associated with COVID‐19 among pregnant women, hospitalization and the Apgar score at 5 min were independently associated with COVID‐19. Cesarean delivery, preterm birth, Apgar scores at 1 and 5 min <7, and maternal death were more frequent in pregnant women with COVID‐19 admitted to ICU than in those not admitted to ICU. Approximately 30% of patients had persistence of symptoms, for at least 6 months in almost 60%. Conclusion: The findings of the present study suggest that COVID‐19 was associated with increased morbidity and mortality among pregnant women. In addition, pregnant women with SARS‐CoV‐2 infection were at significantly higher risk of adverse perinatal outcomes, especially preterm birth.